Home Cart Sign in  
Chemical Structure| 43043-74-9 Chemical Structure| 43043-74-9

Structure of Deoxyshikonin
CAS No.: 43043-74-9

Chemical Structure| 43043-74-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Deoxyshikonin inhibits colorectal cancer (CRC) via the PI3K/Akt/mTOR pathway. It possesses both pro-angiogenic and anti-tumor effects and exhibits antibacterial activity against S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Deoxyshikonin

CAS No. :43043-74-9
Formula : C16H16O4
M.W : 272.30
SMILES Code : CC(C)=CCCC1=CC(=O)C2=C(C(O)=CC=C2O)C1=O
MDL No. :MFCD00144053
InChI Key :VOMDIEGPEURZJO-UHFFFAOYSA-N
Pubchem ID :98914

Safety of Deoxyshikonin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Deoxyshikonin

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 3 µM 24 h Under high glucose conditions, deoxyshikonin promoted tube formation in HUVECs by increasing VEGFR2 expression and phosphorylation of Akt and p38. Int J Mol Sci. 2018 Nov 20;19(11):3660
HOS cells 2.5, 5, 10, 20 μM 24 h To evaluate the effect of deoxyshikonin on HOS cell viability, showing a dose-dependent decrease in cell viability J Cell Mol Med. 2023 Jun;27(11):1592-1602
U2OS cells 2.5, 5, 10, 20 μM 24 h To evaluate the effect of deoxyshikonin on U2OS cell viability, showing a dose-dependent decrease in cell viability J Cell Mol Med. 2023 Jun;27(11):1592-1602
Caco-2 cells 0-100 μg/mL 48 h Deoxyshikonin showed a dose-dependent inhibitory effect on the proliferation of Caco-2 cells. Pharm Biol. 2019 Dec;57(1):412-423
HCT116 cells 0-100 μg/mL 48 h Deoxyshikonin showed a dose-dependent inhibitory effect on the proliferation of HCT116 cells. Pharm Biol. 2019 Dec;57(1):412-423
DLD-1 cells 0-100 μg/mL 48 h Deoxyshikonin significantly inhibited the proliferation of DLD-1 cells and down-regulated the expression of PI3K/Akt/mTOR pathway-related proteins. Pharm Biol. 2019 Dec;57(1):412-423
HT29 cells 0-100 μg/mL 24 or 48 h To evaluate the inhibitory effect of deoxyshikonin on HT29 cell proliferation, results showed that deoxyshikonin exhibited the best inhibitory rate at 48 h with an IC50 of 10.97 μM. Pharm Biol. 2019 Dec;57(1):412-423
SCC-9 cells 2.5 to 40 μM 24 h To evaluate the effect of deoxyshikonin on the viability of tongue cancer cells, results showed that DSK dose-dependently reduced the viability of HSC-3 and SCC-9 cells. Int J Mol Sci. 2022 Jun 26;23(13):7115
HSC-3 cells 2.5 to 40 μM 24 h To evaluate the effect of deoxyshikonin on the viability of tongue cancer cells, results showed that DSK dose-dependently reduced the viability of HSC-3 and SCC-9 cells. Int J Mol Sci. 2022 Jun 26;23(13):7115
IPEC-J2 cells 2.5, 5, 10, 20, 40 μM 24 h Deoxyshikonin pretreatment alleviated the H2O2-induced decrease in cell viability, ROS production, and MMP reduction, but had no significant effect on MDA accumulation and apoptosis. Antioxidants (Basel). 2022 Oct 28;11(11):2134

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Acute gastritis model Gavage 7 mg/kg Once daily for 3 consecutive days Evaluate the therapeutic effect of Deoxyshikonin on H. pylori infection Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0095924
BALB/c nude mice DLD-1 xenograft tumour model Intraperitoneal injection 20 mg/kg Every two days for 13 days To evaluate the inhibitory effect of deoxyshikonin on DLD-1 xenograft tumours, results showed that deoxyshikonin significantly reduced the weight of tumour tissues and down-regulated the expression of PI3K/Akt/mTOR pathway-related proteins. Pharm Biol. 2019 Dec;57(1):412-423

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.67mL

0.73mL

0.37mL

18.36mL

3.67mL

1.84mL

36.72mL

7.34mL

3.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories